Breast cancer claims younger black female lives. If so, when should the screening begin?

Published Date: 26 Apr 2023

Once a woman turns 40, experts advise that she at the very least think about starting a breast cancer screening program. According to a recent study, Black women need this advice above all others.

Read Full News

Latest News



Todays Updates


NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli


Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli


Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C


A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH


The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD


Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial


VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis


REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Todays Updates


NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli


Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli


Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C


A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH


The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD


Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial


VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis


REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

2.

Except for Black Patients, the Rates of Gallbladder Cancer Are Stable or Declining.

3.

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

4.

Kate Middleton Reaches Cancer Treatment Milestone

5.

FDA approves Blenrep for relapsed or refractory multiple myeloma


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot